<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04792489</url>
  </required_header>
  <id_info>
    <org_study_id>M-2018-344</org_study_id>
    <nct_id>NCT04792489</nct_id>
  </id_info>
  <brief_title>DALY 2.0 USA/ MB-CART2019.1 for DLBCL</brief_title>
  <official_title>A Multi-center Single Arm Phase II Study to Evaluate the Safety and Efficacy of Genetically Engineered Autologous Cells Expressing Anti-CD20 and Anti-CD19 Specific Chimeric Antigen Receptor in Subjects With Relapsed and/or Refractory Diffuse Large B Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Miltenyi Biomedicine GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Miltenyi Biomedicine GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open label, single arm, phase II study to determine the efficacy, safety and PK&#xD;
      (persistence) of MBCART2019.1 cells in adults with relapsed or refractory DLBCL after&#xD;
      receiving at least two lines of therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A prospective, single arm, open label, multi-center, phase II study of autologous T cells&#xD;
      engineered against both CD19 and CD20 antigens for subjects with relapsed or refractory DLBCL&#xD;
      after receiving at least two lines of therapy. The investigational agent is the MB-CART2019.1&#xD;
      cells. After successful screening, subjects will undergo leukapheresis to collect product for&#xD;
      manufacturing. In preparation for the fresh product infusion, subjects will undergo a&#xD;
      lymphodepleting regimen with cyclophosphamide and fludarabine. Cell infusion will be&#xD;
      administered intravenously at a dose of 2.5 x 106 CAR+ cells/kg body weight. The study will&#xD;
      start with enrollment of 3 subjects in the lead-in safety phase, and after safety is&#xD;
      evaluated, the study will continue with enrollment of the remaining subjects. Subjects will&#xD;
      be followed for up to 2 years, for efficacy and safety outcomes as well as health-related&#xD;
      quality of life (HRQol). Additional long-term follow-up will be conducted for participants&#xD;
      under a separate long-term follow-up protocol.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 25, 2021</start_date>
  <completion_date type="Anticipated">April 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>1 month</time_frame>
    <description>ORR</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete Response Rate</measure>
    <time_frame>6 months</time_frame>
    <description>CRR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>DOR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>6 months</time_frame>
    <description>ORR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best Overall Response</measure>
    <time_frame>2 years</time_frame>
    <description>BOR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>PFS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>OS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of MB-CART2019.1 [Maximum concentration (Cmax)]</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Bioanalytical</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of MB-CART2019.1 [Time to maximum concentration (Tmax)]</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Bioanalytical</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of MB-CART2019.1 [Area under the curve (AUC)]</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Bioanalytical</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Pharmacodynamics [Levels of cytokines in blood]</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Bioanalytical</description>
  </other_outcome>
  <other_outcome>
    <measure>Correlation of tumor CD19 and CD20 antigen expression with disease progression and relapse</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Bioanalytical</description>
  </other_outcome>
  <other_outcome>
    <measure>Quality of Life (QoL) assessments [EQ-5D-5L]</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Health Outcomes</description>
  </other_outcome>
  <other_outcome>
    <measure>Patient-Reported Outcome (PRO) assessment [FACT-Lym]</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Health Outcomes</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">65</enrollment>
  <condition>DLBCL</condition>
  <arm_group>
    <arm_group_label>Single, open label</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MB-CART2019.1</intervention_name>
    <description>Chimeric antigen receptor (CAR) T cell therapy</description>
    <arm_group_label>Single, open label</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed DLBCL or associated subtype, defined by WHO 2016&#xD;
             classification&#xD;
&#xD;
          -  Relapsed or Refractory disease after 2 or more lines of chemotherapy including&#xD;
             rituximab and anthracycline and either having failed autologous stem cell transplant&#xD;
             (ASCT), or being ineligible for or not consenting to ASCT&#xD;
&#xD;
          -  Age &gt; 18 years&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status that is either 0 or 1 at&#xD;
             screening. ECOG performance status of 2 at screen is allowed if the decrease in&#xD;
             performance status is due to DLBCL&#xD;
&#xD;
          -  Measurable disease according to Lugano 2014 criteria for assessing FDG PET/CT in&#xD;
             lymphoma (Cheson et al, 2014)&#xD;
&#xD;
          -  Subject must have at least 10 unstained slides of tissue available prior to&#xD;
             MBCART2019.1 Infusion. If archival tissue is not available, subject must be willing to&#xD;
             undergo attempted repeat biopsy&#xD;
&#xD;
          -  No clinical suspicion of CNS lymphoma&#xD;
&#xD;
          -  If the subject has history of CNS disease, then he/she must have no signs or symptoms&#xD;
             of CNS disease, have no active disease on magnetic resonance imaging (MRI) and have no&#xD;
             large cell lymphoma present in cerebral spinal fluid (CSF) on cytospin preparation and&#xD;
             flow cytometry, regardless of the number of white blood cells (WBCs)&#xD;
&#xD;
          -  If has history of cerebral vascular accident (CVA), the CVA must be greater than 12&#xD;
             months prior to leukapheresis and any neurological deficits must be stable&#xD;
&#xD;
          -  A creatinine clearance &gt; 60mL/min&#xD;
&#xD;
          -  Cardiac ejection fraction (EF) ≥ 45% as determined by an echocardiogram (ECHO) or&#xD;
             Multigated Radionuclide Angiography (MUGA)&#xD;
&#xD;
          -  Resting O2 saturation &gt;90% on room air&#xD;
&#xD;
          -  Serum alanine aminotransferase (ALT) / aspartate aminotransferase (AST) &lt;5 times the&#xD;
             Upper Limit of Normal (ULN) for age&#xD;
&#xD;
          -  Total bilirubin &lt;1.5 mg/dl, except in individuals with Gilbert's syndrome&#xD;
&#xD;
          -  Absolute neutrophil count &gt; 1000/μL&#xD;
&#xD;
          -  Absolute lymphocyte count &gt; 100/μL&#xD;
&#xD;
          -  Platelet count &gt; 50,000/μL&#xD;
&#xD;
          -  Estimated life expectancy of more than 3 months other than primary disease&#xD;
&#xD;
          -  Subjects of child-bearing or child-fathering potential must be willing to practice&#xD;
             birth control from the time of enrollment on this study until the follow-up period of&#xD;
             the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Primary CNS lymphoma&#xD;
&#xD;
          -  Richter's transformed DLBCL arising from chronic lymphocytic leukemia (CLL)&#xD;
&#xD;
          -  Unable to give informed consent&#xD;
&#xD;
          -  Known history of infection with human immunodeficiency virus (HIV) or active hepatitis&#xD;
             B (HBsAg positive), unless confirmed to be polymerase chain reaction (PCR) negative;&#xD;
             antiviral prophylaxis isrequired if HBsAg negative and anti-HBc positive&#xD;
&#xD;
          -  Known history of infection with hepatitis C virus (anti-HCV positive) unless viral&#xD;
             load is undetectable per quantitative PCR and/or nucleic acid testing&#xD;
&#xD;
          -  Known history of active seizures or presence of seizure activities or on active,&#xD;
             anti-seizure medications within the prior 12 months&#xD;
&#xD;
          -  Known history of CVA within prior 12 months.&#xD;
&#xD;
          -  Known history or presence of autoimmune CNS disease, such as multiple sclerosis, optic&#xD;
             neuritis, or other immunologic or inflammatory disease&#xD;
&#xD;
          -  Presence of CNS disorder that, in the judgment of the investigator, may impair the&#xD;
             ability to evaluate neurotoxicity&#xD;
&#xD;
          -  Active systemic fungal, viral, or bacterial infection&#xD;
&#xD;
          -  Pregnant or breast-feeding woman&#xD;
&#xD;
          -  Previous or concurrent malignancy with the following exceptions:&#xD;
&#xD;
          -  Adequately treated basal cell or squamous cell carcinoma (adequate wound healing&#xD;
             required prior to study entry)&#xD;
&#xD;
          -  In situ carcinoma of the cervix or breast, treated curatively and without evidence of&#xD;
             recurrence for at least 2 years prior to the study&#xD;
&#xD;
          -  Adequately treated breast or prostate carcinoma on hormonal therapies such as Lupron&#xD;
             or tamoxifen and in clinical remission of ≥ 2 years&#xD;
&#xD;
          -  A primary malignancy which has been completely resected / treated with curative intent&#xD;
             and in complete remission of ≥ 2 years&#xD;
&#xD;
          -  History of non-neurologic autoimmune disease (e.g. Crohn's disease, rheumatoid&#xD;
             arthritis, systemic lupus erythematosus)requiring systemic immunosuppressive or system&#xD;
             disease modifying agents within the last 2 years&#xD;
&#xD;
          -  Medical condition requiring prolonged use of systemic corticosteroids equivalent to&#xD;
             prednisone &gt;10 mg/day&#xD;
&#xD;
          -  History of myocardial infarction, cardiac angioplasty or stenting, unstable angina, or&#xD;
             other clinically significant cardiac disease within 6 months of enrollment&#xD;
&#xD;
          -  Concurrent radiotherapy (allow up to time of leukapheresis)&#xD;
&#xD;
          -  Baseline dementia that would interfere with therapy or monitoring, determined using&#xD;
             Immune Effector Cell-Associated Encephalopathy (ICE) Assessment at baseline&#xD;
&#xD;
          -  History of severe immediate hypersensitivity reaction to any of the agents used in&#xD;
             this study&#xD;
&#xD;
          -  Refusal to participate in additional lentiviral gene therapy LTFU protocol&#xD;
&#xD;
          -  Prior CAR-T therapy for any indication&#xD;
&#xD;
          -  Prior allogeneic stem cell transplant for any indication&#xD;
&#xD;
          -  Prior BITE antibodies for cancer therapy&#xD;
&#xD;
          -  Prior T cell receptor-engineered T cell therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Remi Kaleta</last_name>
    <phone>+1 (339) 221-6213</phone>
    <email>remik@miltenyi.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anna Wijatyk</last_name>
    <email>Anna.Wijatyk@miltenyi.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Banner MD Anderson Cancer Center</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <zip>85234</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharan Claire</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julia Jones</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Froedtert Hospital and the Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharon Yim</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 25, 2021</study_first_submitted>
  <study_first_submitted_qc>March 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 11, 2021</study_first_posted>
  <last_update_submitted>July 12, 2021</last_update_submitted>
  <last_update_submitted_qc>July 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chimeric antigen receptor</keyword>
  <keyword>CAR T</keyword>
  <keyword>CD19</keyword>
  <keyword>CD20</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

